QR Kodea

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study

Severe acute respiratory coronavirus-2 (SARS-CoV-2) still presents a public threat and puts extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment options are considered supportive. Tocilizumab as a treatment option has to date shown variable results. In...

Deskribapen osoa

Gorde:
Egile Nagusiak: Ayman M. Al-Qaaneh, Fuad H. Al-Ghamdi, Sayed AbdulAzeez, J. Francis Borgio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2022-03-01
Saila:Pharmaceutics
Gaiak:
COVID-19 patient
tocilizumab
mortality
treatment
ICU admission
monoclonal antibody
Sarrera elektronikoa:https://www.mdpi.com/1999-4923/14/3/624
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak